<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663689</url>
  </required_header>
  <id_info>
    <org_study_id>cslc0803</org_study_id>
    <nct_id>NCT00663689</nct_id>
  </id_info>
  <brief_title>Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Erlotinib in Benefitted Patients With Asymptomatic Brain Metastases Advanced Non-Small Cell Lung Cancer By Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GuangdongPPH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and&#xD;
      toxicity of erlotinib in patients with asymptomatic brain metastasis advanced NSCLC who was&#xD;
      benefitted by first line chemotherapy. Patients with stage IV NSCLC who have one or more&#xD;
      asymptomatic brain metastasis who was benefitted by first line chemotherapy will receive oral&#xD;
      erlotinib 150mg once daily until disease progression or unacceptable toxicity. These&#xD;
      patients' direct DNA sequencing of tumor tissue EGFR exons 18-21 will be analyzed The&#xD;
      response was evaluated by RECIST criteria after the patient received erlotinib 6 weeks.If the&#xD;
      patients present with progress disease of brain metastasis after the therapy of erlotinib,&#xD;
      the patients will receive irradiation of brain metastasis.If the response is stable&#xD;
      disease,partial response or complete response,he will be examined by brain MRI every 12&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of asymptomatic brain metastasis turn into symptomatic brain metastasis</measure>
    <time_frame>3/2008~3/2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine objective response (CR+PR), time to progression, 6-month survival and 1-year survival,safety.</measure>
    <time_frame>3/2008~3/2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>erlotinib 150mg qd until disease progression or unacceptable toxicity.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TARVECA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Histological or cytological documented stage IV NSCLC. Sputum cytology alone is&#xD;
             excluded&#xD;
&#xD;
          2. Extracerebral lesions show stable disease after first line chemotherapy. Patient has&#xD;
             recovered from CTCAE grade 3/4 toxicity. Patients who had never received EGFR-TKI or&#xD;
             EGFR monoclonal antibody.&#xD;
&#xD;
          3. Patients must be at least 18 years.&#xD;
&#xD;
          4. ECOG Performance Status 0, 1 or 2.&#xD;
&#xD;
          5. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          6. Appraisable disease, the presence of at least three lesions if longest diameter &lt;10 mm&#xD;
             by brain MRI.&#xD;
&#xD;
          7. Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count (ANC) ³1.5 x 109/L, platelets ³ 100&#xD;
             x 109/L.&#xD;
&#xD;
          8. Total bilirubin £ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          9. ALT and AST &lt; 2.5 x ULN in the absence of liver metastases, or &lt; 5 x ULN in case of&#xD;
             liver metastases.&#xD;
&#xD;
         10. Creatinine clearance ³ 60ml/min (calculated according to Cockcroft-gault formula).&#xD;
&#xD;
         11. PT-INR/PTT &lt; 1.2 x ULN.&#xD;
&#xD;
         12. Written informed consent.&#xD;
&#xD;
         13. Able to comply with study and follow-up procedures.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Mixed small cell and non-small cell lung cancer histology.&#xD;
&#xD;
          2. Any unresolved toxicity&gt;CTCAE grade 2 from previous anti-cancer therapy.&#xD;
&#xD;
          3. Patients with exposure to biotherapy, immunotherapy within 4 weeks of study entry.&#xD;
&#xD;
          4. Other concurrent anticancer therapy.&#xD;
&#xD;
          5. Patients with exposure to investigational drug therapy outside of this trial.&#xD;
&#xD;
          6. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption&#xD;
             syndrome, or inability to take oral medication, or have active peptic ulcer disease.&#xD;
&#xD;
          7. Any unstable systemic disease (including active infection, hepatic, renal, metabolic&#xD;
             disease or seizure disorder requiring medication).&#xD;
&#xD;
          8. Significant cardiovascular event: congestive heart failure &gt;NYHA class 2; unstable&#xD;
             angina, active CAD (myocardial infarction more than 1 year prior to study entry is&#xD;
             allowed); serious cardiac arrhythmia requiring anti-arrhythmic therapy ( beta blockers&#xD;
             or digoxin are permitted) or uncontrolled hypertension.&#xD;
&#xD;
          9. Brain metastases or spinal cord compression, if treated before the start of study&#xD;
             treatment, and have any symptoms. Symptoms include signs of increased intracranial&#xD;
             pressure ,headache,nausea and vomiting,cognitive or affective&#xD;
             disturbances,seizures,and focal neurologic symptoms.&#xD;
&#xD;
         10. History of another malignancy within the last 5 years except cured carcinoma in-situ&#xD;
             of uterine cervix, cured basal cell carcinoma of skin and superficial bladder tumors&#xD;
             [Ta, Tis &amp; T1].&#xD;
&#xD;
         11. Pregnant or breast-feeding women.&#xD;
&#xD;
         12. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results.&#xD;
&#xD;
         13. Any condition that is unstable or could jeopardize the safety of the patient and their&#xD;
             compliance in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu Yilong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer center of Guangdong PPH</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yilong,Wu</name_title>
    <organization>Guangdong Provincial People's Hospital</organization>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 15, 2014</submitted>
    <returned>April 17, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

